REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug aims to shrink recurrent brain tumors by blocking key growth enzyme
Disease control OngoingThis trial tests the drug savolitinib in children and adults whose brain tumors (medulloblastoma, high-grade glioma, or DIPG) have come back or not responded to treatment. The drug works by blocking an enzyme that some tumor cells need to grow. The study aims to find the safest d…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in Gene-Matched tumors
Disease control OngoingThis study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Childhood cancer immunotherapy trial pulled before it started
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. …
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC